angiotensin II antagonist

One of a range of drugs that act directly on angiotensin at its receptor sites so as to block its action. These drugs include CANDESARTAN, IRBESARTAN, LOSARTAN, VALSARTAN, telmisartan (Micardis), Olmesartan (Olmetec) and eprosartan (Teveten).

Mentioned in ?

References in periodicals archive ?

Racine-Poon, An Interaction Study with Cimetidine and the New Angiotensin II Antagonist Valsartan, Eur.

Liquid Chromatography Method Development and Optimization for Valsartan: Pharmacokinetics of Oral Hydrogels in Rabbits

Antihypertensive medicines dispensed for free during SNP were: (i) beta-blocking agents: atenolol 25 mg and propranolol hydrochloride 40 mg; (ii) diuretics: hydrochlorothiazide 25 mg; and (iii) agents acting on the renin-angiotensin system inhibitors (Class C09 on European Pharmaceutical Marketing Research Association (EphMRA) Anatomical Classification) including (a) the angiotensin-converting-enzyme (ACE) inhibitors captopril 25 mg and enalapril maleate 10 mg; and (b) the angiotensin II antagonist or angiotensin receptor blocker (ARB) losartan potassium 50 mg (10).

Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.

Plasma renin activity and pro-B-type natriuretic peptide levels in different atrial fibrillation types/Farkh atriyal fibrilasyon turlerinde plazma renin aktivitesi ve pro-B-tipi natriuretik peptit duzeyleri

The Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan (HEAAL) trial enrolled patients with symptomatic, New York Heart Association class II-IV heart failure who had a left ventricular ejection fraction of 40% or less.

High losartan dose reduced HF deaths

The principle active valsartan is a nonpeptide, orally active and specific angiotensin II antagonist acting on the [AT.

A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets/Estudio comparativo, cruzado, doble ciego, al azar para determinar la bioequivalencia entre dos formulaciones de valsartan en tabletas y capsulas

Findings from the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) indicate that ARBs are more effective than other agents in slowing the progression of kidney disease in patients with macroalbuminuria due to type 2 diabetes.

ACE inhibitors and ARBs: antihypertensive medications in CKD

COZAAR is the world's most widely prescribed medication in the angiotensin II antagonist class and it continues its strong growth, as physicians increasingly recognize the excellent tolerability and efficacy of these two products.

MERCK'S FIRST QTR. EARNINGS PER SHARE INCREASE 17%

COZAAR is an angiotensin II antagonist (AIIA), cardiovascular medicine approved for three indications:

Higher Dose of Merck's COZAAR[R] (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study

POPULATION STUDIED The Reduction of Endpoints in Non-insulin--dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study included 1513 people with type 2 diabetes and nephropathy, ranging in age from 31 to 70 years.

Does losartan (Cozaar) slow the progression of renal disease in patients with type 2 diabetes and nephropathy? (POEMs)

The supporting data come from several clinical trials, including the Reduction of Endpoints in NID-DM with the Angiotensin II Antagonist Losartan (RENAAL) study, as well as the Irbesartan Diabetic Nephropathy Trial (IDNT).

Slowing nephropathy in hypertensive diabetes

The supporting data come from several clinical trials, including the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, as well as the Irbesartan Diabetic Nephropa thy Trial (IDNT).

ACE inhibitors not best for some hypertensive type 2 diabetics

Medical browser ?

Full browser ?

CITE

Site: Follow: Share:

Open / Close